Introduction
Pancreatic cancer is one of the most lethal and challenging cancers to treat. It is often diagnosed at a late stage, when the tumor has already spread to other organs or blood vessels. The only curative option for patients with pancreatic cancer is surgery, but not all patients are eligible for it. Moreover, surgery can be associated with high rates of complications and mortality. Therefore, there is a need for new and improved surgical techniques that can increase the chances of survival and quality of life for patients with pancreatic cancer.
In this blog, we will review some of the latest advancements in pancreatic surgery that have been reported in the recent literature. These include:
-
The use of minimally invasive techniques, such as laparoscopy and robotics, that can reduce the trauma and blood loss during surgery, and improve the recovery and outcomes of patients.
-
The use of neoadjuvant therapy, such as chemotherapy and radiation, that can shrink the tumor and make it more resectable, and improve the survival and recurrence rates of patients.
-
The use of liquid biopsies, such as blood tests that can detect cancer cells or DNA, that can help diagnose, monitor, and personalize the treatment of pancreatic cancer.
-
The use of molecular markers and genetic testing, that can identify the subtype and characteristics of the tumor, and guide the selection of the most effective and targeted therapies.
Minimally Invasive Techniques
Traditionally, pancreatic surgery has been performed through a large incision in the abdomen, called open surgery. However, this approach can cause significant trauma, blood loss, pain, and infection, and prolong the hospital stay and recovery time of patients. In recent years, minimally invasive techniques, such as laparoscopy and robotics, have been developed and refined to overcome these limitations. Laparoscopy involves the use of a thin tube with a camera and instruments that is inserted through small incisions in the abdomen. Robotics involves the use of a computer-controlled device that mimics the movements of the surgeon’s hands and allows more precise and delicate manipulation of the tissues.
Several studies have shown that minimally invasive techniques can offer several advantages over open surgery, such as:
-
Less blood loss and transfusion
-
Less pain and narcotic use
-
Less wound infection and hernia
-
Shorter hospital stay and faster recovery
-
Better cosmetic results
-
Similar or better survival and recurrence rates
However, minimally invasive techniques also have some challenges and limitations, such as:
-
Longer operative time and higher cost
-
Steep learning curve and technical difficulty
-
Limited availability and expertise
-
Higher risk of conversion to open surgery
-
Uncertain long-term outcomes and complications
Therefore, minimally invasive techniques should be performed by experienced and skilled surgeons, in selected and suitable patients, and in specialized and well-equipped centers.
Neoadjuvant Therapy
Another advancement in pancreatic surgery is the use of neoadjuvant therapy, which is the administration of chemotherapy and/or radiation before surgery. The rationale behind this strategy is to:
-
Shrink the tumor and make it more resectable, especially if it involves the blood vessels or other organs
-
Eradicate the microscopic cancer cells that may have spread beyond the primary tumor
-
Select the patients who are most likely to benefit from surgery, based on their response to the therapy
-
Improve the survival and recurrence rates of patients after surgery
Several clinical trials have demonstrated the benefits of neoadjuvant therapy in pancreatic cancer, such as:
-
Increased resection rate and margin-negative rate
-
Decreased lymph node involvement and metastasis rate
-
Improved overall survival and disease-free survival
-
Reduced postoperative complications and mortality
However, neoadjuvant therapy also has some drawbacks and challenges, such as:
-
Delayed surgery and potential tumor progression
-
Toxicity and side effects of the therapy
-
Lack of standardized and optimal regimen and duration
-
Lack of reliable and objective criteria to assess the response and eligibility for surgery
Therefore, neoadjuvant therapy should be tailored to each patient, based on their tumor type, stage, and characteristics, and their general health and preferences. It should also be delivered in a multidisciplinary setting, involving surgeons, oncologists, radiologists, pathologists, and other specialists.
Liquid Biopsies
A liquid biopsy is a non-invasive test that can detect cancer cells or DNA in a patient’s blood or other body fluids. It can provide valuable information about the diagnosis, prognosis, and treatment of pancreatic cancer, such as:
-
Early detection of pancreatic cancer, which is often asymptomatic and difficult to diagnose using conventional methods, such as imaging or tissue biopsy
-
Monitoring of the disease progression and response to therapy, by measuring the changes in the amount and type of cancer cells or DNA over time
-
Personalization of the treatment, by identifying the specific mutations and alterations that drive the growth and survival of the cancer cells, and selecting the most effective and targeted therapies accordingly
Several studies have shown that liquid biopsies can offer several advantages over tissue biopsies, such as:
-
Less invasive and painful
-
More accessible and repeatable
-
More representative and comprehensive
-
More sensitive and specific
However, liquid biopsies also have some limitations and challenges, such as:
-
Low quantity and quality of cancer cells or DNA in the blood
-
High variability and complexity of the results
-
Lack of standardization and validation of the methods and platforms
-
Lack of clinical utility and evidence of the impact on outcomes
Therefore, liquid biopsies should be used as a complementary and supplementary tool to tissue biopsies, and in conjunction with other clinical and pathological parameters. They should also be performed and interpreted by experienced and qualified professionals, and in accredited and certified laboratories.
Molecular Markers and Genetic Testing
The last advancement in pancreatic surgery that we will discuss is the use of molecular markers and genetic testing, which are methods that can identify the subtype and characteristics of the tumor at the molecular level, such as the genes, proteins, and pathways that are involved in the development and progression of the cancer. They can provide useful information about the prognosis and treatment of pancreatic cancer, such as:
-
Prediction of the survival and recurrence rates of patients after surgery, based on the expression and activity of certain biomarkers, such as CA19-9, CEA, K-ras, p53, and others
-
Selection of the most appropriate and effective therapies for each patient, based on the presence or absence of certain mutations and alterations, such as BRCA1, BRCA2, MSI, PD-L1, and others
-
Prevention and screening of pancreatic cancer, especially in high-risk individuals, such as those with a family history or inherited syndromes, by testing for certain genes that increase the susceptibility to the disease, such as BRCA1, BRCA2, PALB2, and others
Several studies have shown that molecular markers and genetic testing can offer several benefits in pancreatic cancer, such as:
-
Improved stratification and risk assessment of patients
-
Enhanced precision and personalization of treatment
-
Increased response and survival rates of patients
-
Reduced toxicity and side effects of treatment
-
Increased awareness and counseling of patients and relatives
However, molecular markers and genetic testing also have some drawbacks and challenges, such as:
-
High cost and complexity of the tests
-
Limited availability and accessibility of the tests
-
Low frequency and diversity of the mutations and alterations
-
Lack of consensus and guidelines on the selection and interpretation of the tests
-
Lack of ethical and legal regulations on the use and disclosure of the results
Therefore, molecular markers and genetic testing should be performed and interpreted in a careful and responsible manner, and in a multidisciplinary and collaborative setting. They should also be integrated and correlated with other clinical and pathological parameters, and with the patient’s preferences and values.
Conclusion
Pancreatic surgery is a complex and challenging procedure that can offer a chance of cure for patients with pancreatic cancer. However, it is not without risks and limitations, and it requires a high level of expertise and experience. In recent years, several advancements have been made in the field of pancreatic surgery, such as minimally invasive techniques, neoadjuvant therapy, liquid biopsies, and molecular markers and genetic testing. These advancements have the potential to improve the outcomes and quality of life of patients with pancreatic cancer, by increasing the resectability and survival rates, reducing the complications and mortality rates, and personalizing the treatment and care. However, these advancements also pose some challenges and difficulties, such as technical difficulty, cost, availability, standardization, validation, and utility. Therefore, these advancements should be used with caution and discretion, and in a comprehensive and holistic approach, that considers the patient’s tumor type, stage, and characteristics, as well as their general health and preferences.
How may we assist you today?
If you have any concerns about symptoms related to pancreatic disorders, do not hesitate to contact us and arrange an appointment. Our team of surgeons is dedicated to delivering exceptional care to patients, with a primary focus on their well-being and safety. Our objective is to address your worries and equip you with the necessary information to make an educated decision regarding your health. You can be confident that our surgeons possess extensive training and experience in their field.
